Literature DB >> 32413561

Sellar-Suprasellar Paraganglioma: Report of 2 Cases and Review of Literature.

Pavan Vasoya1, Saritha Aryan1, Sumit Thakar2, Laxminadh Sivaraju1, Nandita Ghosal3, Alangar S Hegde1.   

Abstract

BACKGROUND: Intracranial paragangliomas are infrequent and those occurring in the sellar-suprasellar region are rare, with only 31 cases described in literature. CASE DESCRIPTION: We describe 2 cases of sellar-suprasellar paragangliomas in the light of a literature review. The first patient was a 13-year-old boy who presented with an intensely enhancing lesion in the sellar-suprasellar region with multiple flow voids within. Resection of the lesion was limited to a biopsy in view of its hypervascular nature. A second attempt at resection following partial embolization of the lesion was also unsuccessful. The tumor showed progressive reduction in size following radiotherapy. The second case was a 20-year-old man who presented with a similar tumor in the same location. He also had a probable metastatic deposit in the foramen of Magendie. An attempted surgical resection of the suprasellar lesion was abandoned after a biopsy. The patient improved symptomatically after radiotherapy.
CONCLUSIONS: We report 2 cases of paraganglioma occurring in a rare location. Presence of flow voids within tumors in the sellar-suprasellar location should alert the surgeon to this entity. The hypervascular nature of these tumors may limit the extent of resection. In cases of inadequate tumor decompression, or if there is evidence of growth of residual tumor, radiotherapy can help to stabilize the disease.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Paraganglioma; Sellar; Suprasellar

Year:  2020        PMID: 32413561     DOI: 10.1016/j.wneu.2020.04.157

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  1 in total

1.  Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features.

Authors:  Stefan Stojanoski; Henning Bünsow Boldt; Dusko Kozic; Attila Patócs; Márta Korbonits; Milica Medic-Stojanoska; Olivera Casar-Borota
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.